<DOC>
<DOCNO>EP-0645139</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Use of (S)-(-)-alpha-ethyl-2-oxo-1-pyrrolidine-acetamide for the preparation of a medicament for the treatment of anxiety
</INVENTION-TITLE>
<CLASSIFICATIONS>A61P2522	C07D20700	A61K3140	A61K3140	A61K314015	A61P2518	A61K314015	C07D20727	A61P2520	A61P2500	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61P	C07D	A61K	A61K	A61K	A61P	A61K	C07D	A61P	A61P	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61P25	C07D207	A61K31	A61K31	A61K31	A61P25	A61K31	C07D207	A61P25	A61P25	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Use of (S)-(-)- alpha -ethyl-2-oxo-1-pyrrolidineacetamide of formula   
<
IMAGE
>
 as a medicament for the treatment of anxiety.t
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
UCB SA
</APPLICANT-NAME>
<APPLICANT-NAME>
UCB, S.A.
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
COSSEMENT ERIC
</INVENTOR-NAME>
<INVENTOR-NAME>
GOBERT JEAN
</INVENTOR-NAME>
<INVENTOR-NAME>
GOWER ALMA
</INVENTOR-NAME>
<INVENTOR-NAME>
WUELFERT ERNST
</INVENTOR-NAME>
<INVENTOR-NAME>
COSSEMENT, ERIC
</INVENTOR-NAME>
<INVENTOR-NAME>
GOBERT, JEAN
</INVENTOR-NAME>
<INVENTOR-NAME>
GOWER, ALMA
</INVENTOR-NAME>
<INVENTOR-NAME>
WUELFERT, ERNST
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Use of (S)-(-)-α-ethyl-2-oxo-1-pyrrolidineacetamide of
formula



for the preparation of drugs intended for the treatment of
anxiety.
Use of (S)-(-)-α-ethyl-2-oxo-1-pyrrolidineacetamide
according to claim 1 for the preparation of drugs intended

for the treatment of anxiety states caused by acute post-traumatic
stress.
Use of (S)-(-)-α-ethyl-2-oxo-1-pyrrolidineacetamide
according to claim 1 for the preparation of drugs intended

for the treatment of anxiety induced by the withdrawal of
the chronic administration of benzodiazepines.
Use according to any one of claims 1 to 3,
characterized in that the effective therapeutic quantity of

the compound of formula I is comprised between 5 and
70 mg/kg per day.
</CLAIMS>
</TEXT>
</DOC>
